The trial met its primary objectives, showing the pill’s effectiveness in helping patients with Type 2 diabetes achieve improved blood sugar control and weight loss.

Over the last couple of years, one of the best pharma stocks to own has been Eli Lilly ( LLY 14.56%). But now, an investment in Lilly may not look so enticing as the possibility of more tariffs loom. Let's explore how tariffs would impact Eli Lilly's business, and assess whether investors should buy the stock now or run for the hills instead.

Shares of Eli Lilly jumped 16% Thursday morning after the pharmaceutical company released clinical trial results for its oral weight-loss drug that "demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines.